TB-500

Prices & lab reports (COAs)

Amino Club sells TB-500 as a research chemical. Its listings are research-use-only and not for human use; we show them for price tracking and their published lab reports.

Affiliate link: we may earn a commission at no cost to you. Disclosure

All TB-500 lab reports, lot by lot →

• Look for a batch-specific COA with HPLC purity (≥98%) and mass-spec identity.
• Common vial sizes (any seller): 5, 10 mg. Amino Club lists 10 mg.

Mixing (reconstitution)

Diluent: Bacteriostatic water (0.9% benzyl alcohol) — allows multiple draws from one vial.

1. Wipe both vial tops with an alcohol swab and let dry.
2. Draw the diluent, then inject it slowly down the inside wall of the vial — never straight onto the powder.
3. Swirl gently or let it sit; do not shake. Foam can damage peptides.
4. Solution should be clear. Cloudy, stringy or discolored = discard.
5. Common mix: 5 mg + 2 mL = 2.5 mg/mL (2 mg = 80 units).

Full reconstitution guide →

Storage

• Large injection volumes at 2 mg — consider mixing with less diluent so the dose fits comfortably.

Side effects & cautions

Legal status: FDA, international and WADA

Regulations change often — verify with the FDA, EMA, MHRA, Health Canada, TGA and WADA before acting.

Often paired with

FAQ

Related reading

• Blog · Oct 27, 2026Six peptides got a panel yes vote. Here's what that does and doesn't meanA July FDA advisory panel reportedly voted yes on six peptides, including BPC-157 and TB-500. A yes vote isn't approval, so here is what the research shows.
• Blog · Oct 22, 2026TB-500 explained: what the research shows and how it differs from thymosin beta-4TB-500 is hugely popular for injury recovery. Here is what rat studies, reviews and early case reports show, and why thymosin beta-4 and TB-500 are not the same thing.
• Blog · Oct 10, 2026WADA's 2027 Prohibited List: what changes for peptides and GLP-1 drugsWADA's 2027 list now names "peptides" in general as banned at all times, while semaglutide and tirzepatide stay permitted but monitored.
• Blog · Oct 1, 2026FDA's 2026 peptide compounding changes, explainedIn April the FDA took 12 peptides off its compounding safety-concern list, and in July an advisory panel voted on seven. Here is what each step means, and what it doesn't.
• Blog · Oct 1, 2026BPC-157 in 2026: what the evidence actually showsBPC-157 has well over a hundred animal studies and only a handful of tiny human reports behind it. Here is what is known, what is not, and where it stands with the FDA and WADA.
• Blog · Jul 23, 2026The most-researched peptides of 2026, ranked by evidenceTwelve peptides people ask about most, sorted by how much human evidence stands behind them, from approved drugs down to compounds with almost no human data.
• Podcast · Oct 28, 2026Six peps got a panel yes vote. What that does and doesn't meanA reported FDA panel yes vote isn't an approval. Mark and Amy look at the research behind BPC-157 and TB-500, both at 2 of 5, and what a vote can and can't tell you.
• Podcast · Oct 15, 2026BPC-157 in 2026: what the evidence actually showsMark and Amy sort out what BPC-157's evidence really shows: decades of animal studies, a handful of tiny human reports, unknown safety, a WADA ban, and an FDA advisory vote that hasn't changed the law.

Sources

• Read the primary research on PubMed ↗
• Registered human trials on ClinicalTrials.gov ↗

See something wrong or out of date? Report an error and we’ll check it against the sources. How we review pages